Intracervical prostaglandin in postdate pregnancy. A randomized trial

Area of Science:

• Obstetrics and Gynecology
• Reproductive Medicine

Background:

• Postdate pregnancy, defined as gestational age of 41 6/7 weeks or greater, poses risks.
• Cervical ripening agents are used to improve obstetric outcomes in these cases.

Purpose of the Study:

• To evaluate the efficacy of intracervical prostaglandin E2 (PGE2) in managing postdate pregnancies.
• To determine if PGE2 administration affects labor induction, delivery, and neonatal outcomes.

Main Methods:

• A double-blind, placebo-controlled study randomized 43 postdate pregnant patients.
• Patients received either 0.5 mg of PGE2 gel or a placebo inserted into the cervical canal.
• Outcomes assessed included Bishop score, time to delivery, labor induction, cesarean rates, and neonatal status.

Main Results:

• No significant differences were observed between the PGE2 and placebo groups in most outcomes.
• A higher incidence of labor onset within 72 hours was noted in the PGE2 group, though not statistically significant.
• Obstetric and neonatal outcomes were largely similar between groups.

Conclusions:

• Intracervical PGE2 administration at 41 6/7 weeks gestation, without subsequent oxytocin, did not significantly change obstetric outcomes.
• Further research may be needed to clarify the role of PGE2 in specific patient populations or with different protocols.